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Abstract
Background: Precursor T-cell lymphoblastic lymphomas (T-LBL) are rare aggressive hematological malignancies that
mainly develop in children. As in other cancers, the loss of cell cycle control plays a prominent role in the
pathogenesis in these malignancies that is primarily attributed to loss of CDKN2A (encoding protein p16INK4A).
However, the impact of the deregulation of other genes such as CDKN1C, E2F1, and TP53 remains to be clarified.
Interestingly, experiments in mouse models have proven that conditional T-cell specific deletion of Cdkn1c gene
may induce a differentiation block at the DN3 to DN4 transition, and that the loss of this gene in the absence of
Tp53 led to aggressive thymic lymphomas.
Results: In this manuscript, we demonstrated that the simultaneous deregulation of CDKN1C, E2F1, and TP53 genes
by epigenetic mechanisms and/or the deregulation of specific microRNAs, together with additional impairing of
TP53 function by the expression of dominant-negative isoforms are common features in primary human T-LBLs.
Conclusions: Previous experimental work in mice revealed that T-cell specific deletion of Cdkn1c accelerates
lymphomagenesis in the absence of Tp53. If, as expected, the consequences of the deregulation of the CDKN1C-
E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis
might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential
therapeutic strategiesin human T-LBL.
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Background
Precursor T-cell lymphoblastic neoplasms are aggressive
haematological malignancies that mainly develop in chil-
dren (in particular adolescent males) but also in adults.
They derive from maturing thymocytes leading to exces-
sive lymphoblastoid cells in the bone marrow and other
lymphoid organs. Clinically, T-cell acute lymphoblastic
leukaemia (T-ALL) and T-cell lymphoblastic lymphoma
(T-LBL) are two subgroups differing by the extent of
bone marrow infiltration. T-ALL manifests with exten-
sive bone marrow and blood affectation, whereas a mass
lesion in the thymus/anterior mediastinum with less
than 25% of lymphoblasts in the bone marrow character-
izes T-LBL [1].
As in other cancers, the loss of cell cycle control plays
a prominent role in the pathogenesis of these malignan-
cies that is primarily attributed to loss of CDKN2A
(which encodes the tumour suppressor protein
p16INK4A) and, to a lesser extent, loss of RB1 or
CDKN1B (which encodes p27/KIP1 protein) and aber-
rantly high levels of CCND2 (encoding cyclin D2) [2].
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Downregulation of CDKN1C (which encodes p57/KIP2
protein) by promoter hypermethylation has been de-
tected with very low frequency in paediatric T-ALL and
more often in adult patients. However, the biological
and clinical impact of hypermethylation and/or loss of
CDKN1C expression remain uncertain [3]. In addition
to T-ALL, downregulation of CDKN1C has been
observed more frequently in a wide variety of human tu-
mours associated with a strengthening of cell prolifera-
tion [4, 5].
In addition, numerous studies have reported that E2F1
overexpression has clinical relevance in many types of
cancers [6]. However, to the best of our knowledge,
E2F1 alterations have not been so far implicated in the
development of precursor T-cell neoplasms.
Moreover, the gene encoding TP53 protein, a main
downstream effector of E2F1, is frequently targeted in
human tumours by gene mutations [7, 8]. Apart from
the canonical full-length transcript, it should be noted
that alternative splicing of TP53 and the use of alternate
promoter might result in multiple transcript variants
and isoforms [9] and, interestingly, abnormal expression
of TP53 isoforms has been reported in many cancers as
head and neck, acute myeloid leukaemia (AML) and
breast tumours [10] but not in T-cell lymphoblastic
neoplasms.
The potential nexus between these three genes has
been demonstrated in mice. Some authors [11] have
shown in mouse models that inactivation of the Cdkn1c
gene (also termed as p57KIP2) results in thymocyte
development arrest at DN3 (Double-Negative 3) to DN4
cells transition, due to hyper-activation of the E2f-Tp53
pathway. Furthermore, the loss of Cdkn1c accelerates
the development of thymic lymphomas in the absence of
the Tp53 gene.
To assess whether the axis CDKN1C/E2F1/TP53 plays
a role in human T-cell lymphoblastic lymphomas, we in-
vestigated the mutational status and the expression
levels of these three genes using Next-Generation
Sequencing (NSG) approaches. Interestingly, RNA-
Sequencing analysis revealed reduced levels of CDKN1C
mRNA in almost all analysed T-LBL samples, which
may be accompanied by increased expression of E2F1
and overexpression of the TP53 transcript variant encod-
ing the Δ133TP53 isoform. Deregulation of these genes




Human T-LBL samples separated in an exploratory co-
hort (8 samples), an extended cohort (10 samples), and
four thymuses of human foetus without haematological
pathology, were obtained from the Spanish Hospital
Biobanks Network (RetBioH; www.redbiobancos.es).
Lymphomas were diagnosed according to World Health
Organization Classification of Hematological Malignan-
cies and recommendations from the European childhood
lymphoma pathology panel [12, 13] (Additional file 1:
Table S1). Institutional review board approval was
obtained for these studies (reference CEI:70–1260).
RNA-sequencing
Total RNA was obtained using TriPure Reagent (Roche
Applied Science, Indianapolis, IN, USA), following man-
ufacturer’s instructions.
Massive sequencing of mRNAs
RNA Integrity Numbers (RIN) were in the range of
7.2–9.8. Image analysis, per-cycle basecalling and
quality score assignment were performed with
Illumina Real Time Analysis software (Illumina, San
Diego, CA). BCL files were converted to FASTQ for-
mat with Illumina’s Off-Line Basecaller package
(Illumina). The resulting directional RNA-seq libraries
were sequenced in paired-end format in two different
rounds (Illumina HiSeq2000), leading to 50 bp and
76 bp reads (the latter were trimmed to 50 bp). Sequenced
reads were quality-checked with FastQC (http://www.bio
informatics.babraham.ac.uk/projects/fastqc/). RNA-seq
reads were aligned to the human genome (GRCh37/hg19)
with TopHat-2.0.10 [14] (using Bowtie 1.0.0 [15] and
Samtools 0.1.19 [16]) allowing two mismatches and five
multihits. Transcripts assemblies, estimation of their
abundances were calculated with Cufflinks 2.2.1, using the
Ensembl GRCh37.74 annotation for human. In this ana-
lysis, we only considered the transcripts isoforms of the
genes CDKN1C, E2F1 and TP53 that encode for proteins
according to the information showed in Ensembl [17].
Small RNA
Image analysis and per-cycle basecalling was performed
with Illumina Real Time Analysis software (RTA1.9)
(Illumina). Conversion to FASTQ read format was per-
formed by CASAVA-1.8 (Illumina). Small-RNA-seq li-
braries were sequenced as 40 bp single-end reads
(Illumina Genome Analyzer IIx, GAIIx). Sequenced
reads were quality-checked with FastQC. Sequence
adapters were removed with cutadapt v1.2.1 [18] and
only those reads longer than 15 bp and shorter than
35 bp were kept for further analysis. Reads were aligned
to the human genome (GRCh37/hg19) with Bowtie 1.0.0
[15] and Samtools 0.1.19 [16] allowing no mismatches
and a maximum of one alignment per read. Raw counts
for miRNAs were obtained with HTSeq v0.5.3p9 [19],
using the miRBase v20 [20] annotation for hg19. A table
with normalized read counts was generated with DESeq
[21] and was used to filter out miRNAs with
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questionable expression and outliers. The following cri-
teria were used: first, we required that a miRNA should
have a minimal normalized count value of 15 in at least
5% of the samples. Second, miRNAs with normalized
expression values across the samples that exceeded Q1–
3*IQR or Q3 + 3*IQR were considered outliers and dis-
carded. For the remaining miRNAs, log2 fold-changes of
expression were calculated.
Raw sequencing data and transcripts expression quan-
tification is available as a superseries in GEO (Gene Ex-
pression Omnibus) under the following ID: GSE109234.
Additional criteria to select miRNAs
To select those miRNA controlling CDKN1C, E2F1 and
TP53 genes, we used the databases of miRGate and miR-
TarBase. We select those miRNAs experimentally vali-
dated (“Functional miRNA-target interactions (MTI)”
registered in “Support type” of miRTarBase and/or
“Functional MTI” registered in the miRGate “Confirmed
predictions”) and/or those microRNA that showed a
“miRGate Agreement Score” equal or higher than the
median agreement-value of the microRNA identified as-
sociated with the genes assessed (median value = 1.04).
(Additional file 2: Figure S1).
Additionally, we filtered out miRNAs showing a num-
ber of counts lower than 28.70 (median value of the
miRNA counts of all the samples) in any sample
(Additional file 3: Figure S2).
Quantitative RT-PCR
RNA was reverse-transcribed using first the High-
Capacity RNA-to-cDNA™ Kit (Applied Biosystems,
Foster City, CA, USA) and MystiCq microRNA cDNA
Synthesis Mix (Sigma-Aldrich, St. Louis, MO, USA).
Quantitative real-time PCR reactions were performed
in triplicate with an Applied Biosystems 7300 Real-
Time PCR system (Life Technologies, Carlsbad, CA),
using either the Fast Start Universal SYBRGreen Mas-
ter (Rox) (Roche) or the MystiCq microRNA SYBR
Green qPCR ReadyMix (Sigma-Aldrich), according to
the manufacturers’ instructions. Expression values of
β-2-microglobulin or β-actin or SNORD48 served to
normalize using the 2-ΔΔC T method [22]. Primers
are indicated in Additional file 4: Table S2.
Targeted gene deep sequencing and sanger sequencing
Mutational status of CDKN1C, E2F1 and TP53 genes
was analysed by targeted deep sequencing in genomic
using a selected panel of cancer-related genes (the
OncoNIM® Seq409 panel; New Integrated Medical gen-
etics; NIMGenetics, Madrid, Spain). Sanger DNA se-
quencing of PCR-amplified mutational hot spots was
performed with the specific primers summarized in
Additional file 4: Table S2.
Bisulfite genomic sequencing and methylation-specific
PCR (MSP)
Methyl Primer Express v1.0 software (Applied Biosystems)
was used to identify CpG islands around the Transcrip-
tional Star Site (TSS) of CDKN1C gene, and to design spe-
cific primers for the methylation analysis. DNA (1 μg) was
subjected to sodium bisulfite treatment using the EZ
DNA Methylation-Gold kit (Zymo Research, CA, USA).
MSP was performed with primers specific for methylated
(M) or unmethylated (U) CpG sites. For bisulfite genomic
sequencing, a region included in the one analysed by MSP
was amplified using 1 μL of bisulfite-converted DNA with
Immolase Taq polymerase (Bioline USA Inc., Kenilworth,
NJ) at 60 °C for 40 cycles. Then the resulting PCR prod-
ucts were gel-purified (2% agarose) with Wizard® SV Gel
and PCR Clean-Up System (Promega, Madison, WI, USA)
and cloned into the pGEMT Easy Vector System
(Promega) following the manufacturer-specific protocols.
For all samples, 12 colonies were randomly chosen, and
DNA was purified using Wizard® Plus SV Minipreps DNA
Purification System (Promega) and sequenced with a ABI
3730 xl DNA Analyzer (Applied Biosystems). After se-
quencing analysis, the results were transformed into per-
centages of CpGs calculated in comparison with the total
CpGs of the analysed region. Primers and conditions are
indicated in Additional file 4: Table S2.
Statistical analyses
Differential expression of mRNA and miRNA (RNA-
Seq) between tumours and controls was estimated by
calculating the log2 Fold changes (log2FC) of the expres-
sion levels. Only differential expression levels estimated
by the Cufflinks software as “OK” were taken into ac-
count. Significant deregulated miRNAs with log2FC ab-
solute values equal or higher than 1.5 in at least in one
sample were selected according to the information of
miRGate and miRTarBase databases [23, 24] and add-
itional criteria based on the read counts [25]. Student’s
t-test was used to compare results from qRT-PCR be-
tween tumours and controls. All statistical analyses were
performed using R software.
Results
Deregulation of CDKN1C, E2F1 and TP53 in T-LBLs
The results of massive RNA-sequencing (RNA-Seq) of
the transcript isoforms that encode proteins in the 8 T-
LBL samples of the exploratory cohort showed that the
mRNA level of CDKN1C was strongly reduced in all
analysed tumours compared to that of the normal foetal
thymuses, with fold-changes ranging from − 25.99 to −
2.15 in the canonical isoform ENST00000414822. By
contrary, the expression of E2F1 gene in the same panel
increases in all tumours, three of them with fold-
changes higher than 1.5. Concerning the transcriptional
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status of the TP53 gene, we found increased levels of the
transcript variant encoding the dominant-negative
Δ133p53α protein isoform (TP53–008: ENST00000504937)
in all but two of the eight tumours (fold-changes between
3.26 and 0.74). Moreover, two of them (346 and 460) exhib-
ited a clear reduction of two transcript variants (TP53–001:
ENST00000269305 and TP53–002: ENST00000445888)
encoding full-length TP53 protein isoforms (TAp53α).
Finally, two tumours (192 and 521) showed increased
amounts of the TP53β transcript (ENST00000420246),
which encodes a C-terminal truncated protein (Figs. 1
and 2; Additional file 5: Table S3).
These results were validated by quantitative real-time
RT-PCR (qRT-PCR) analysis and confirmed in the ex-
tended cohort (Fig. 3; Additional file 6: Table S4). Inter-
estingly, all samples in the extended cohort showed a
significant reduction of CDKN1C expression, six out of
ten showed significant increases of E2F1 expression, and
six out of ten exhibited significant increases of the
mRNA isoform encoding Δ133p53α protein.
Overrepresentation of the arginine allele at codon 72 of
TP53 in T-LBLs
The analysis of T-LBLs by targeted gene deep sequen-
cing revealed the existence of two missense mutations.
One of them was c.427G > T (p.Val143Leu) at exon 5 in
sample 192, with conflicting interpretations of pathogen-
icity in the IARC database [26]. The other missense
mutation was the functional polymorphism c.215C > G
(p.Pro72Arg) that was found in all but one analysed tu-
mours (8/9), three of them being homozygotes for the
arginine allele (238, 521, and 840) (Additional file 7:
Table S5) (Fig. 2). However, we were able to validate only
the mutation at exon 4 by DNA Sanger-sequencing (data
not shown) using the primers and conditions indicated
in Additional file 4: Table S2.
Epigenetic modifications contribute to the altered
expression of CDKN1C in a fraction of T-LBLs
The CDKN1C gene is remarkably rich in CpG islands
situated both upstream and downstream from the tran-
scriptional start site, whose hypermethylation has been
strongly related to its inactivation [27]. To elucidate
whether aberrant DNA methylation is a mechanism
whereby CDKN1C was downregulated in our T-LBLs,
we analysed the DNA methylation levels of the
promoter region of CDKN1C gene using the MSP/Se-
quencing method. We initially examined six samples of
normal foetal thymuses by MSP, confirming the
absence of methylated bands in all cases (data not
shown). However, although all samples in the explora-
tory cohort exhibited significant downregulation of this
gene, only two tumours exhibited high levels of hyper-
methylation (521 and 840), suggesting additional mech-
anisms to explain CDKN1C downregulation in the
remaining samples (Fig. 4).
Fig. 1 Deregulation of CDKN1C, E2F1 and TP53 in T-LBLs of the exploratory cohort by RNA-Seq. Numbers indicate log2 Fold changes (log2FC) between
the expression of mRNAs in tumours and controls. Positive and negative values represent overexpression and reduced expression, respectively
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MicroRNA deregulation contributes to the deregulation of
CDKN1C, E2F1 and TP53 genes in T-TLBLs
Aberrant expression of microRNAs (miRNAs) in human
tumours and links between deregulated miRNAs and
target genes involved in cell cycle have been well estab-
lished [28, 29].
Differences in the expression level of the selected
miRNA were initially determined by massive small
RNA-sequencing (RNA-Seq) in the 8 T-LBL samples of
the exploratory cohort. There were only two significant
deregulated miRNAs controlling CDKN1C expression,
which are up-regulated in practically all the samples
(miR-221–3p and miR-222-3p). We also found seven
deregulated miRNAs to target E2F1 transcript, especially
emphasizing the importance of miR-203a and miR-205-
5p that were strongly down-regulated. Finally, 17 miR-
NAs to target TP53 transcripts were deregulated
highlighting the levels of miR-200a-3p and miR-375
downregulation of (Fig. 5; Additional file 8: Table S6).
Deregulation of these miRNAs was confirmed by qRT-
PCR in the exploratory cohort and in the extended cohort
of T-LBL samples (Fig. 6; Additional file 9: Table S7).
Discussion
It is well established that CDKN1C and E2F1 are two
critical controllers of the cell cycle. The overexpression
of CDKN1C may cause cell cycle arrest in human
tumour cell lines [30, 31], and this inhibitory effect may
be reversed by siRNAs against the CDKN1C gene [32].
In contrast, knockdown of E2F1 by RNA interference
impairs proliferation of rat glioma cells [33]. Import-
antly, previous experimental work in mice reported that
conditional T cell-specific deletion of Cdkn1c gene in-
duced a differentiation block in mouse immature thymo-
cytes that is caused by hyperactivation of E2f1 and Tp53
and may be predisposed to thymic lymphoma develop-
ment. Moreover, Cdkn1c ablation led to the development
of aggressive thymic lymphomas with a reduced latency
in a Tp53-null background. Thus, these results suggested
a critical role for the Cdkn1c-E2f1-Tp53 axis in mouse
thymic lymphoma development [11, 34].
Our results show that all analysed human T-LBL sam-
ples exhibited a strong downregulation of CDKN1C. In
addition, most of them also exhibited upregulation of
E2F1 (6/8 in the exploratory cohort and 6/10 in the ex-
tended cohort), which may be accompanied by impair-
ment of TP53 function in some cases (4/6 in the
exploratory cohort and 6/10 in the extended cohort)
(Fig. 1; Additional file 3: Table S3 and Additional file 4:
Table S4). Thus, our data are consistent with the exist-
ence and deregulation of a CDKN1C-E2F1-TP53 axis in
human T-LBL. However, it should be noted that our
study is largely based on the expression of these genes at
the transcriptional level. The relationship between
mRNA and protein expression levels is dependent on
the combined outcomes of mRNA stability, translation,
and protein degradation. Notwithstanding, it has been
reported that at least 30 to even 85% of the variation in
protein levels can be attributed to variation in mRNA
expression [35]. Other authors [36] reported that differ-
entially expressed mRNAs correlate significantly better
with their protein product than non-differentially
expressed mRNAs, therefore providing some optimism
for the usefulness on inferences from mRNA expression
in general.
Concerning the mechanisms by which these genes are
deregulated, it is well known that CDKN1C is subject to a
complex regulation involving the cooperation of a CpG is-
land at its promoter region and distal regulatory elements,
such as the imprinting control region Kv-Differentially
a
b
Fig. 2 TP53 mutations and isoforms showing differential expression in our sample series of T-LBL. a Genomic representation of the TP53 gene
showing the two missense mutations at exons 4 and 5 we detected in these samples. Alternative splicing of intron 9 generates p53 isoforms
bearing different C-terminal domains (α, β and γ). b TP53 isoforms that showed differential levels of expression in our tumours. TAp53 isoforms include
p53 (p53α), p53β and p53γ, whereas Δ133p53 isoforms include Δ133p53α, Δ133p53β and Δ133p53γ. TP53 protein domains: transactivation domains
(TA), proline rich domain (PXXP), DNA binding domain (DNA BD), nuclear localization signal (NLS) and oligomerization domain (OD)
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Methylated Region 1 (KvDMR1) in the promoter of the
noncoding KCNQ1OT1 [37, 38]. Although the biological
and clinical impact of CDKN1C hypermethylation is ra-
ther uncertain, aberrant DNA methylation of CDKN1C in
its promoter region has been reported in lymphoid malig-
nancies of B and T-cell phenotype [39, 40]. However,
CDKN1C has been reported downregulated in other type
of cancer cells mainly by histone modifications operating
in critical regions of its promoter [41, 42]. We initially
focused on promoter hypermethylation to explain down-
regulation of this gene in our sample series of T-LBL, but
despite a substantial reduction in the levels of mRNA in
almost all samples in the exploratory cohort (7/8), only
two samples (840 and 521) (2/8) exhibited significant
hypermethylation density (Fig. 4), and six out of eight
(including tumor 840 with promoter hypermethylation)
exhibited upregulation of one or two miRNAs selected for
CDKN1C regulation (miR-211–3p and miR-222-3p).
Fig. 3 Differential expression of CDKN1C, E2F1 and TP53 in T-LBLs of the exploratory cohort by quantitative RT–PCR. Relative expression values
were calculated as the mRNA amount of each gene relative to that of either β-actin or β2 microglobulin (used as reference) and normalized to
the relative expression of normal control samples (foetal thymuses). Each bar represents the mean ± SD of three independent experiments.
Differences in expression values were statistically significant (p < 0.05)
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Thus, downregulation of CDKN1C in two samples (33
and 346) should be explained by a different transcriptional
mechanism.
Besides this epigenetic mechanism, regulation by miR-
NAs might be an additional way contributing to deter-
mine CDKN1C transcript levels in T-LBLs. Results
reported here are in line with those reported in the lit-
erature describing miR-25, miR-221 and miR-222 as dir-
ect regulators of CDKN1C expression in a wide variety
of solid tumours, showing a new mechanism responsible
for CDKN1C downregulation in carcinogenesis [43–45].
In this context, our findings suggest that aberrant ex-
pression of miR-221 and miR-222 may have an onco-
genic function in T-LBL development by targeting
CDKN1C. However two samples (33 and 346) showed a
pronounced downregulation of CDKN1C in the absence
of significant changes in miRNA expression (Figs. 5 and 6)
or promoter CpG methylation, thus indicating that the
mechanism regulating the expression of this gene is far
more complex.
Overexpression of E2F1 may promote proliferation or
cell cycle progression by increasing the transcription of
genes that contribute to G1-S transition [46]. Notwith-
standing at the same time it may also induce apoptosis
by multiple pathways, some of which induce stabilization
and activation of the TP53 protein [47]. Our microRNA
analysis also revealed a consistent deregulation of seven
miRNAs in T-LBLs, miR-203a and miR-205-5p being
the most representative downregulated microRNAs
(Figs. 5 and 6). Interestingly, downregulated miRNAs
Fig. 4 Schematic depiction of the CpG-island around the transcription start site of CDKN1C (TSS). ATG indicate the position of the translation start
site. Short vertical lines represent CpG dinucleotides. Methylated (black circles) or unmethylated (white circles) CpG sites are indicated in 12
sequenced clones for every tumour. Methylation density is indicated as the percentage of methylated sites in comparison with total CpG sites
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showed higher fold changes than upregulated micro-
RNAs. miR-205-5p is known to be down-regulated in
melanoma and its expression inversely correlated with
that of E2F1 [48].
Concerning impairing of TP53 function, we found
overexpression of the human Δ133p53αisoform in 4
samples from the exploratory cohort, from which three
also exhibited downregulation of the isoform encoding
Fig. 5 Deregulated MicroRNA controlling CDKN1C, E2F1 and TP53 genes in T-LBLs of the exploratory cohort (RNA-Seq). Numbers indicate log2
Fold changes (log2FC) between the miRNAs read counts in tumours and controls. Positive and negative values represent up-regulated and
down-regulated, respectively. Only miRNAs showing log2FC absolute values equal or higher than 1.5 in at least in one sample are depicted.
The number in each column represents the sample identifier
López-Nieva et al. BMC Cancer  (2018) 18:430 Page 8 of 12
full length TAp53α protein isoforms (Figs. 1 and 2). It
has been demonstrated that Δ133p53α does not exclu-
sively function in a dominant-negative manner toward
TAp53α, the full-length TP53 isoform [49], but it also in-
hibits TP53-dependent apoptosis [50]. Finally, two tu-
mours (192 and 521) showed increased amounts of the
TP53β transcript, which encodes a C-terminal truncated
protein that downplay TP53 capacity to induce apoptosis
[9, 51]. These changes in the expression levels of full
length and shorter isoforms may be sustained, at least in
part, by deregulation of 17 miRNAs, with particular ref-
erence to miR-200a-3p and miR-375 that exhibited very
high levels of downregulation in all samples in the ex-
ploratory cohort (Figs. 5 and 6).
But impairment of the TP53 function could be also at-
tributed to the overrepresentation of the arg72 allele in
our sample series (Fig. 2). It is known that the TP53
gene is not only frequently mutated in human tumours
Fig. 6 Differential expression of miRNAs regulating CDKN1C, E2F1 and TP53 expression by interaction with its 3’UTR. Transcriptional levels of
hsa-miR-200a-3p, hsa-miR-203, hsa-miR-205-5p, hsa-miR-221–3p, hsa-miR-222-3p, hsa-miR-25-3p and in human T-LBLs were measured using
qRT-PCR assay. Relative expression values were calculated as the mRNA amount of each gene relative to miR-SNORD48 (used as reference) and
normalized to the relative expression of normal control samples (foetal thymuses). Each bar represents the mean ± SD of three independent
experiments. Differences in expression values were statistically significant (p < 0.05)
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[7], but it also contains several functional polymor-
phisms, being by far the most common a proline (Pro)
to arginine (Arg) change at codon 72 in the TP53 pro-
tein [10]. Several studies have reported preferential re-
tention of arg72 allele in squamous cell carcinomas of
the vulva [52], head and neck [53], and esophagus [54].
Considering tumour tissue DNA, Schneider-Stock et al.
[55] found a significantly higher frequency of the arg72
allele in colorectal tumours and reported that the pres-
ence of this allele correlates with the malignant potential
of the tumour. Similar results were also reported in urin-
ary tract cancers [56] and lung cancer [57]. The arg72 al-
lele was also related with increased risk for bladder
cancer [58].
Conclusions
Our results indicate the existence of a CDKN1C-E2F1-
TP53 axis that is disrupted in a significant fraction of
human T-LBLs. If, as expected, the consequences of the
deregulation of the CDKN1C-E2F1-TP53 axis were the
same as those experimentally demonstrated in mouse
models, deregulation of this axis in human T-LBL might
serve as a biomarker to predict the aggressiveness of T-
LBL development as depicted in Fig. 7. Furthermore,
these findings would provide the basis to the develop-
ment of potential therapeutic strategies based on the
use of microRNAs (mimics or antagomirs) to target
CDKN1C or E2F1 deregulation that allow to rescue
normal thymocyte differentiation and normal levels of
thymocytes proliferation in patients with T-LBL.
Blocking E2F1 expression by RNA interference might
represent a promising therapeutic approach in this
type of tumours. Future studies with new samples
series of T-LBL should be done to be sure that the
differences detected at the mRNA level translate into
the protein level, and to confirm that the deregulation
of this axis in human samples is really predictive of
clinical outcome.
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